Clinical and paraclinical characteristics of optic neuritis in the context of the McDonald criteria 2017.
Clinically isolated syndrome
Diagnostic criteria
McDonald Criteria
Multiple sclerosis
Optic neuritis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Mar 2024
27 Mar 2024
Historique:
received:
19
10
2023
accepted:
15
03
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
epublish
Résumé
Optic neuritis is often an initial symptom in multiple sclerosis (MS) or clinically isolated syndrome (CIS), yet comprehensive studies using the 2017 McDonald criteria for MS are scarce. Patient records from our academic centre (2010-2018) were reviewed. Using the 2017 McDonald criteria, three groups were formed: MS optic neuritis (optic neuritis with confirmed MS), CIS optic neuritis (optic neuritis without confirmed MS) and suspected optic neuritis (sON). We compared clinical and paraclinical findings among the groups to identify predictors for CIS- or MS-optic neuritis. The study included 129 MS, 108 CIS, and 44 sON cases. The combination of visual impairment, dyschromatopsia, and retrobulbar pain was observed in 47% of MS patients, 42% of CIS patients, and 30% of sON patients. Dyschromatopsia was the strongest indicator of MS or CIS diagnosis in the backward regression model. 56% of MS patients had relative afferent pupillary defect, 61% optic nerve anomalies within magnetic resonance imaging, and 81% abnormal visual evoked potentials. Our results emphasize the challenges in diagnosing optic neuritis, as not all patients with objectively diagnosed MS exhibit the triad of typical symptoms. To address potentially missing clinical features, incorporating additional paraclinical findings is proposed.
Identifiants
pubmed: 38538701
doi: 10.1038/s41598-024-57199-4
pii: 10.1038/s41598-024-57199-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7293Informations de copyright
© 2024. The Author(s).
Références
Toosy, A. T., Mason, D. F. & Miller, D. H. Optic neuritis. Lancet Neurol. 13, 83–99 (2014).
doi: 10.1016/S1474-4422(13)70259-X
pubmed: 24331795
Optic Neuritis Study Group. The clinical profile of optic neuritis: Experience of the optic neuritis treatment trial. Arch. Ophthalmol. 109, 1673–1678 (1991).
doi: 10.1001/archopht.1991.01080120057025
Hoorbakht, H. Optic neuritis, its differential diagnosis and management. Open Ophthalmol. J. 6, 65–72 (2012).
doi: 10.2174/1874364101206010065
pubmed: 22888383
pmcid: 3414716
Voss, E., Raab, P., Trebst, C. & Stangel, M. Clinical approach to optic neuritis: Pitfalls, red flags and differential diagnosis. Ther. Adv. Neurol. Disord. 4, 123–134 (2011).
doi: 10.1177/1756285611398702
pubmed: 21694809
pmcid: 3105615
Deschamps, R. et al. Acute optic neuritis: What are the clues to the aetiological diagnosis in real life?. Mult. Scler. Relat. Disord. 76, 1047 (2023).
doi: 10.1016/j.msard.2023.104764
Lin, C.-W., Chen, W.-T., Lin, Y.-H., Hung, K. & Chen, T.-C. Clinical characteristics and prognosis of optic neuritis in Taiwan—a hospital-based cohort study. Mult. Scler. Relat. Disord. 75, 104739 (2023).
doi: 10.1016/j.msard.2023.104739
pubmed: 37148579
Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018).
doi: 10.1016/S1474-4422(17)30470-2
pubmed: 29275977
Sergott, R. C. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. Yearb. Ophthalmol. 2009, 187–188 (2009).
doi: 10.1016/S0084-392X(09)79112-9
Brownlee, W. J., Hardy, T. A., Fazekas, F. & Miller, D. H. Diagnosis of multiple sclerosis: Progress and challenges. The Lancet 389, 1336–1346 (2017).
doi: 10.1016/S0140-6736(16)30959-X
McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121–127 (2001).
doi: 10.1002/ana.1032
pubmed: 11456302
Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58, 840–846 (2005).
doi: 10.1002/ana.20703
pubmed: 16283615
Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann. Neurol. 69, 292–302 (2011).
doi: 10.1002/ana.22366
pubmed: 21387374
pmcid: 3084507
Petzold, A. et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 21, 1120–1134 (2022).
doi: 10.1016/S1474-4422(22)00200-9
pubmed: 36179757
Solomon, A. J. et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology 87, 1393–1399 (2016).
doi: 10.1212/WNL.0000000000003152
pubmed: 27581217
pmcid: 5047038
Solomon, A. J. & Corboy, J. R. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat. Rev. Neurol. 13, 567–572 (2017).
doi: 10.1038/nrneurol.2017.106
pubmed: 28799551
Wingerchuk, D. M. International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (Springer, 2015).
doi: 10.1212/WNL.0000000000001729
Jarius, S. et al. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J. Neuroinflamm. 15, 134 (2018).
doi: 10.1186/s12974-018-1144-2
Schwenkenbecher, P. et al. McDonald criteria 2010 and 2005 compared: Persistence of high oligoclonal band prevalence despite almost doubled diagnostic sensitivity. Int. J. Mol. Sci. 17, 1592 (2016).
doi: 10.3390/ijms17091592
pubmed: 27657060
pmcid: 5037857
Schwenkenbecher, P. et al. Clinically isolated syndrome according to McDonald 2010: Intrathecal IgG synthesis still predictive for conversion to multiple sclerosis. Int. J. Mol. Sci. 18, 2061 (2017).
doi: 10.3390/ijms18102061
pubmed: 28953254
pmcid: 5666743
Gingele, S., Jendretzky, K. F., Bajor, A., Meuth, S. G. & Skripuletz, T. Application of diagnostic criteria for optic neuritis. Lancet Neurol. 22, 375–376 (2023).
doi: 10.1016/S1474-4422(23)00112-6
pubmed: 37059501
Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K. & Bach, M. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch. Clin. Exp. Ophthalmol. 247, 137–142 (2009).
doi: 10.1007/s00417-008-0926-0
pubmed: 18766368
Schwenkenbecher, P. et al. Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis. BMC Neurol. 16, 136 (2016).
doi: 10.1186/s12883-016-0657-5
pubmed: 27515847
pmcid: 4981998
Waters, P. et al. Multicentre comparison of a diagnostic assay: Aquaporin-4 antibodies in neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 87, 1005–1015 (2016).
doi: 10.1136/jnnp-2015-312601
pubmed: 27113605
Reindl, M. et al. International multicenter examination of MOG antibody assays. Neurol. Neuroimmunol. Neuroinflamm. 7, e674 (2020).
doi: 10.1212/NXI.0000000000000674
pubmed: 32024795
pmcid: 7051197
Gingele, S. et al. Routine cerebrospinal fluid cytology reveals unique inclusions in macrophages during treatment with nusinersen. Front. Neurol. 10, 735 (2019).
doi: 10.3389/fneur.2019.00735
pubmed: 31354609
pmcid: 6637748
Reiber, H. Cerebrospinal fluid–physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult. Scler. J. 1998, 99–107. https://doi.org/10.1177/135245859800400302 (1998).
doi: 10.1177/135245859800400302
Andersson, M. et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J. Neurol. Neurosurg. Psychiatry 57, 897–902 (1994).
doi: 10.1136/jnnp.57.8.897
pubmed: 8057110
pmcid: 1073070
Reiber, H. External quality assessment in clinical neurochemistry: Survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin. Chem. 41, 256–263 (1995).
doi: 10.1093/clinchem/41.2.256
pubmed: 7874779
Filippi, M. et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: Practical guidelines. Brain 142, 1858–1875 (2019).
doi: 10.1093/brain/awz144
pubmed: 31209474
pmcid: 6598631
Kallmann, B. A., Fackelmann, S., Toyka, K. V., Rieckmann, P. & Reiners, K. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult. Scler. J. 12, 58–65 (2006).
doi: 10.1191/135248506ms1244oa
Giffroy, X. et al. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis. BMC Neurol. 16, 83 (2016).
doi: 10.1186/s12883-016-0608-1
pubmed: 27245221
pmcid: 4888661
Sharma, R. Visual evoked potentials: Normative values and gender differences. J. Clin. Diagn. Res. https://doi.org/10.7860/JCDR/2015/12764.6181 (2015).
doi: 10.7860/JCDR/2015/12764.6181
pubmed: 26816984
pmcid: 4717822
Sarin, S. et al. Predicting the final clinical phenotype after the first attack of optic neuritis. J. Neuroimmunol. 381, 578130 (2023).
doi: 10.1016/j.jneuroim.2023.578130
pubmed: 37343437